<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a variety of recent studies, inhibitors of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) synthesis have ameliorated neuronal injury during permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, suggesting that NO may contribute to ischemic damage </plain></SENT>
<SENT sid="1" pm="."><plain>In other studies, however, these inhibitors increased <z:mpath ids='MPATH_124'>infarct</z:mpath> volume during permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="2" pm="."><plain>One complication in these studies was that high-dose NO synthase inhibitors increased mean arterial blood pressure (MAP) by 20-30 mm Hg </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, it is possible that variations in the effects of NO synthesis inhibitors on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume could be related to effects of these inhibitors on MAP and cerebral perfusion during or after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The present study compared the effects of control (Ringer's <z:chebi fb="4" ids="24996">lactate</z:chebi> solution) versus low-dose NO inhibition (0.1 mg/kg bolus followed by 0.01 mg/kg/min) on cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume using L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (NG-<z:chebi fb="13" ids="29785">nitro</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi>) administered during a 1-h baseline period, 3-h of MCAO, and 2 h of reperfusion in the spontaneously hypertensive rat </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was determined using the TTC (2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi>) method performed 5 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of occlusion </plain></SENT>
<SENT sid="6" pm="."><plain>L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 55% </plain></SENT>
<SENT sid="7" pm="."><plain>In the control group (n = 7), <z:mpath ids='MPATH_124'>infarct</z:mpath> volume measured 116 +/- 4 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) mm3 which was 29 +/- 1% of the left hemispheric volume (400.5 +/- 0.3 mm3) </plain></SENT>
<SENT sid="8" pm="."><plain>In the L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> group (n = 7), <z:mpath ids='MPATH_124'>infarct</z:mpath> volume measured 53 +/- 8 mm3 which was only 13 +/- 2% of the left hemispheric volume (400.4 +/- 0.5 mm3).(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>